Skip to content

Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI in Kernan in 2022

Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151004024335N5
Enrollment
288
Registered
2022-08-09
Start date
2022-03-21
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Complication associated with artificial fertilization, unspecified

Interventions

Intervention 1: Intervention group: Intervention group: To start the IUI cycle, women are given ovulation-stimulating drugs in the form of letrozole or clomiphene tablets for five days from the third

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Infertile women with unexplained infertility Infertility with a mild male factor Infertility due to polycystic ovary syndrome who have not responded to drug treatment alone Age 18 to 40 years

Exclusion criteria

Exclusion criteria: Three times more history of unsuccessful intra uterine sperm insemination treatment azoospermia or Severe spermogram disorder Presence of endocrine diseases such as diabetes and severe thyroid disease

Design outcomes

Primary

MeasureTime frame
Chemical pregnancy. Timepoint: 14 days after embryo transfer. Method of measurement: Measurement of serum beta-HCG.

Secondary

MeasureTime frame
Clinical pregnancy. Timepoint: Five weeks after embryo transfer. Method of measurement: Transvaginal ultrasound.;Miscarriage rate. Timepoint: miscarriages before 20 weeks gestation. Method of measurement: Contact patients at the 20th week of pregnancy.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRobabe Hosseinisadat

Kerman University of Medical Sciences

robabehosseinisadat@yahoo.com+98 34 3132 8486

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026